AU771819B2 - Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof - Google Patents
Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof Download PDFInfo
- Publication number
- AU771819B2 AU771819B2 AU38091/00A AU3809100A AU771819B2 AU 771819 B2 AU771819 B2 AU 771819B2 AU 38091/00 A AU38091/00 A AU 38091/00A AU 3809100 A AU3809100 A AU 3809100A AU 771819 B2 AU771819 B2 AU 771819B2
- Authority
- AU
- Australia
- Prior art keywords
- light
- sensitive
- stability
- components
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000001225 therapeutic effect Effects 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 18
- 239000000126 substance Substances 0.000 claims description 33
- 239000013543 active substance Substances 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 16
- 229960004340 lacidipine Drugs 0.000 claims description 13
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000011888 foil Substances 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 9
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 5
- 239000011241 protective layer Substances 0.000 claims description 5
- 230000005670 electromagnetic radiation Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000009931 harmful effect Effects 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 7
- 229960002715 nicotine Drugs 0.000 description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 101100453960 Drosophila melanogaster klar gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101100168117 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) con-8 gene Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229940072101 nimotop Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Process for increasing the stability during storage and/or application of light-sensitive therapeutic systems or components thereof The invention relates to a process for increasing the stability during storage and/or application of light-sensitive therapeutic systems or components thereof, such as active substances or auxiliary substances, using light stability agents absorbing or reflecting electromagnetic waves.
o: The invention further relates to administration forms such 0"0 as therapeutic systems or the components thereof wherein the stability of light-sensitive parts or components is increased by means preventing the access of stabilityimpairing electromagnetic radiation or of other influences such as, for instance, aerial oxygen.
The causes of the instability of an administration form are ~of a twofold nature. On the one hand, it is the lability of %009 the pharmaceutical active agents or the auxiliary agents 00 themselves, which ultimately results from their chemical or 0:0. physico-chemical structure, on the other hand, it is the S. S external factors, such as temperature, humidity, atmospheric oxygen and light, which induce or accelerate reactions diminishing efficacy.
The degree to which these factors become effective is to a large extent dependent on the galenic composition of the preparations.
Generally, it is possible to distinguish between physical, chemical and microbial instability. Physical stabilityimpairing processes can be, for example: a change in the crystal structure a change in the state of distribution a change in the consistency or state of aggregation a change in the relations of solubility, or a change in the relations of hydration Stability-impairing chemical reactions are, for example: hydrolysis oxidation reduction steric rearrangement decarboxylation or polymerisation.
Frequently, it is practically impossible to assign a particular instability exactly to one of the above categories since in many cases complex interactions are involved the results of which can be determined or perceived only through their final effect.
In known measures of stabilisation, the protection against light is of great significance. Action of light can impair the stability of an active substrate itself, but also the stability of the auxiliary agents employed. Thus, for instance, storage of oxidation-sensitive substances in lightproof or partially translucent vessels, e.g. porcelain jars or vessels of brown glass, is well known and absolutely imperative in order to ensure sufficient storage stability.
Investigations have shown that it is always only a particular spectral range of light which is responsible for lightinduced instabilities. It has further been shown that the most effective protection against light is attained by substances or measures the absorption maxima of which lie in the region of those wavelengths which are mainly responsible for the degradation. This fact will in the following be illustrated in detail by way of examples: In the case of the example of the very light-sensitive vitamine A acid an active agent used for treating acne vulgaris it was possible to show that the instability thereof is caused mainly by electromagnetic waves having a wavelength of 400 nm. It was further shown that by using a yellow colourant having its absorption maximum in the range of the wavelength mentioned, the rate of degradation of the active substance can be substantially reduced. Other measures, for instance, the use of light-stability or screening agents, which absorb UV-A or UV-B rays and are commonly used in sun cremes, did not yield the desired results.
(Briseart, Plaizier-Vercammen; Investigation on the Photostability of Tretinoin Lotion and Stabilization with Additives; Proc. 2nd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; AGPI/APV, e. Paris, 25-28 May 1998, 1231-1232).
1,4-Dihydropyridine derivatives are known to be very lightsensitive. 1,4-Dihydropyridines are medicinally used as socalled calcium channel blockers. The active substance group serves to treat hypertension and the coronary diseases.
Examples are nifidipine (Adalat®), nitrendipine (Bayotensin®), nimodipine (Nimotop®), felodipine (Modip®), nicardipine (Antagonil@), lacidipine (Motens®), nisoldipine 0" (Baymycard®), nilvadipine (Escor®), isradipine (Lomir@), amlodipine (Norvasc®). Due to their physico-chemical properties, 1,4-dihydropyridine derivatives are suitable for transdermal application.
It is further known that the type of packaging has a strong influence on the stability of the 1,4-dihydropyridine derivates. The stability can be increased by addition of light-absorbing or light-reflecting additives. In the case of the example of the yellow-coloured nifidipine it was possible to prove the influence differently coloured packages have on stability. The best results were achieved where active substance-containing tablets were packed in a green blister pack. The protection against light weakened increasingly from yellow to red to orange. No protection was obtained from blue or colourless press-through packs, so-called blister packs. The use of UV-A radiationabsorbing substances did not lead to an improvement.
It results therefrom that the best protection is ensured by films/foils whose absorption spectrum comprises that wavelength which is responsible for the degradation of the active substance.
It was possible to further increase the protection afforded by such coloured films/foils by incorporating opalescent substances such as titanium dioxide.
A large number of pharmaceutical substances which are components of transdermal therapeutic systems or formulations show light-sensitive behaviour and are degraded when exposed for a prolonged period to the influence of light. To increase their stability, in-particular during storage, it is therefore necessary to provide special light protection.
To this end, different measures have been known, and described in the literature.
0 WO 91/09731 describes a packaging material suitable for long-term storage of nicotine preparations. To produce the packaging material, a laminate is used which serves as a barrier. In this function, the laminate is intended to neutralise the influence of different external factors, such as air, water and/or light, which impair the stability of nicotine.
US 5.008,110 describes a transdermal patch used, for example, for administration of buprenorphine. A characteristic feature is that this transdermal therapeutic system (TTS) is encapsulated in a hermetically sealed compartment protecting the formulation from environmental factors.
The protective action is obtained by using materials that are impermeable to air, water and light. This measure increases the stability of the preparation and ensures efficacy.
US 4,597,961 describes a TTS for administering nicotine. This TTS consists of a carrier film, a film permeable to nicotine, a matrix containing the nicotine, and an adhesive for attaching the TTS on the skin. A characteristic feature is that the carrier film is impermeable to air, water and light.
The impermeability to air and light protects the nicotine against degradation, and the water-impermeability prevents nicotine diffusion.
The measures described above offer a general protection.
Films/foils or laminates are used which constitute a part of the primary packaging or of the therapeutic systems. The characteristic feature of these measures is that they do not offer specific protection but rather aim at protecting the therapeutic systems against environmental influences in general. In this context, the factors air, water and light have been mentioned.
ooooo According to a first aspect, the present invention consists o of a process for increasing the stability during storage oooo and/or application of light-sensitive transdermal therapeutic systems containing light-sensitive active substances and/or Slight-sensitive auxiliary substances, using light-stability agents absorbing or reflecting electromagnetic waves, characterized in that coloured polymers, films or foils are oo ~used as absorption or reflection agents for the production of oooo one or more components of said systems, and that the oooo absorption or reflection spectrum of said absorption or reflection agents comprises that wavelength range which is **oO° 6 responsible for the instability of the light-sensitive active substances and/or light-sensitive auxiliary substances, and said components are selected from a backing layer, a membrane which controls the release of an active substance, a polymercontaining active substance or auxiliary substance, a pressure-sensitive adhesive layer, and a removable protective layer.
According to a second aspect, the invention consists of a transdermal therapeutic system containing light-sensitive active substances and/or light-sensitive auxiliary substances characterised in that the stability of light-sensitive substances is increased by means for preventing the access of stability-impairing electro-magnetic radiation wherein at least one of the components of the transdermal therapeutic system contains absorption or reflection agents selected from the group consisting of coloured polymers, films or foils wherein the absorption or reflection spectrum of the coloured polymers, films or foils comprises that range of wavelengths which is responsible for the instability of the lightsensitive active substances and/or light-sensitive auxiliary substances, and said components are selected from a backing layer, a membrane which controls the release of an active substance, a polymer-containing active substance or auxiliary substance, a pressure-sensitive adhesive layer, and a removable protective layer.
go The invention will in the following be illustrated by way of an example: gee °oo o C C• C C C Example: Increasing the stability by use of coloured polymers As a representative of the very light-sensitive 1,4dihydropyridine derivatives, lacidipine is used. By way of the example of lacidipine it is possible to show the influence the absorption spectrum of a polymer, for instance, one based on polypropylene, has on the stability of the 1,4dihydropyridine derivative.
To carry out the experiment, the lacidipine was dissolved in a solvent. Since dissolved lacidipine is very sensitive to electromagnetic radiation, it was possible to clearly determine the influence of the polymers examined. The lacidipine solution was filled in differently coloured vessels of polypropylene and exposed to daylight for a defined period of time. The vessels in this context served as models for a coloured film. After the vessels had been exposed to a certain radiation (for a time of 6 to 8 hours), the lacidipine content of the samples was determined. On o*oooo *o*o *o the basis of the known initial concentration and the detected active substance amounts it was possible to make a statement on the protective action of the polymers used.
The results showed that the most efficient light protection is ensured if the absorption spectrum of the polymer employed comprises that region of wavelengths which is responsible for the instability of the lacidipine. The results are listed in the following Table 1: 0 g e.
S. 0
C
0O 0 0 gee.
S
*0@O 0000 Table 1: Colour of the poly- Absorption range Amount of active mer substance after irradiation of initial amount] green, clear <325 nm; >800 nm 12.40 transparent, clear <300 nm 14.79 orange, klar 550 nm 750 nm 15.65 transparent, cloudy <300 nm 21.05 blue, clear <325 nm; 23.46 500 nm 700 nm yellow, clear <350 nm; 29.32 >700 nm brown, clear <500 nm 98.93 aluminized lichtundurchlassig 99.36 The absorption spectrum of lacidipine contains three maxima [238.4 nm; 282.8 nm; 367.4 nm]. These wavelength regions determine the light-sensitivity of the active substance. As can be seen from the table, only the brown-coloured (respectively, the aluminized) polypropylene includes the entire absorption spectrum of the lacidipine and thus affords sufficient protection from light. It can thus be con- 8 cluded that to ensure maximum stability in the present case brown or aluminized polymers should be used.
Further embodiments of the invention are provided in accordance with the sub-claims.
Finally, the invention comprises an administration form in which the stability of light-sensitive parts or components is substantially increased by means for preventing the access of stability-impairing components such as air, water and/or light, by the fact that said means include materi- 0 als, such as glas, films/foils, polymers etc. whose absorption or reflection spectrum comprises that region of wavelengths which is responsible for the degradation of active •00 substances or auxiliary substances, and which are impermeable at least to the access of air and light.
*0 0 0 O iD oo o
Claims (14)
1. Process for increasing the stability during storage and/or application of light-sensitive transdermal therapeutic systems containing light-sensitive active substances and/or light- sensitive auxiliary substances, using light-stability agents absorbing or reflecting electromagnetic waves, characterized in that coloured polymers, films or foils are used as absorption or reflection agents for the production of one or more components of said systems, and that the absorption or reflection spectrum of said absorption or reflection agents comprises that wavelength range which is responsible for the instability of the light-sensitive active substances and/or light-sensitive auxiliary substances, and said components are selected from a backing layer, a membrane which controls the release of an active substance, a polymer- containing active substance or auxiliary substance, a pressure-sensitive adhesive layer, and a removable protective layer.
2. Process according to claim 1, characterized in that the stability of light-sensitive materials is increased by addition of light-absorbing or light-reflecting material(s).
3. Process according to one or more of claims 1 or 2, characterized in that the protection of light-sensitive, in particular, therapeutic materials is accomplished by films/foils, whose absorption or reflection spectrum comprises those wavelengths which are responsible for the light-induced degradation or weakening of the active substance or auxiliary substance.
4. Process according to one or more of claims 1 to 3, characterized in that as light- stability filter there are used materials whose absorption or reflection maxima lie within the region of those wavelengths responsible for the degradation of the active substances or auxiliary substances to be protected.
Process according to one or more of claims 1 to 4, characterized in that to produce packages for light- and environment-sensitive active substances or auxiliary substances, there are used laminates, films/foils or polymers which serve as barrier against the harmful effect of light, air or humidity and which, apart from being capable of absorbing or reflecting aggressive light rays, are impermeable to aerial oxygen and humidity.
6. Process according to one or more of claims 1 to 5, characterized in that for a membrane of a therapeutic system or preparation, which membrane controls the release rate of an active substance, there is used a material having a barrier function against light, aerial oxygen and/or humidity.
7. Process according to one or more of claims 1 to 6, characterized in that to increase the stability of light-sensitive components of a therapeutic preparation or system, at least one component of the backing layer is formed as a light barrier.
8. Process according to one or more of claims 1 to 6, characterized in that to increase the stability of light-sensitive components of a therapeutic preparation or system, at least one component of the polymer-containing active substance or auxiliary substance is formed as a light barrier.
9. Process according to one or more of claims 1 to 6, characterized in that to increase the stability of light-sensitive components of a therapeutic preparation or system, at least one component of the pressure-sensitive adhesive layer and/or of a removable protective layer is formed as a light barrier.
Process according to one or more of claims 1 to 9, characterized in that to increase the stability of light-sensitive or oxidation-sensitive components of active substance, auxiliary substance or other system components, a primary package or secondary package is used i consisting of materials which are light-absorbing and/or impermeable to aerial oxygen and/or light-reflecting.
11. Process according to claim 1, characterized in that as light-sensitive component there is used a 1,4-dihydropyridine, preferably lacidipine.
12. A transdermal therapeutic system containing light-sensitive active substances and/or light-sensitive auxiliary substances characterised in that the stability of light-sensitive substances is increased by means for preventing the access of stability-impairing electro- 0 Ol magnetic radiation wherein at least one of the components of the transdermal therapeutic S system contains absorption or reflection agents selected from the group consisting of coloured 11 polymers, films or foils wherein the absorption or reflection spectrum of the coloured polymers, films or foils comprises that range of wavelengths which is responsible for the instability of the light-sensitive active substances and/or light-sensitive auxiliary substances, and said components are selected from a backing layer, a membrane which controls the release of an active substance, a polymer-containing active substance or auxiliary substance, a pressure-sensitive adhesive layer, and a removable protective layer.
13. Administration form according to claim 12, containing as light-sensitive component 1,4-dihydropyridine, preferably lacidipine.
14. Process for increasing the stability during storage and/or application of light-sensitive therapeutic systems and/or components thereof, such as active substances or auxiliary substances, using light-stability agents absorbing or reflecting electromagnetic waves, said process being substantially as herein described. Administration form such as a therapeutic preparation, system or components thereof, in which the stability of light-sensitive parts or components is increased by means for o preventing the access of stability-impairing electromagnetic radiation or other influences such as, for instance, aerial oxygen, said administration form being substantially as herein described. Dated this 21st day of January 2004 oooo LTS LOHMANN THERAPIE-SYSTEME AG HODGKINSON AND McLNNES Patent Attorneys for the Applicant
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19912623A DE19912623A1 (en) | 1999-03-20 | 1999-03-20 | Process for increasing the stability when storing and / or using light-sensitive therapeutic systems or their components |
| DE19912623 | 1999-03-20 | ||
| PCT/EP2000/001986 WO2000056289A1 (en) | 1999-03-20 | 2000-03-08 | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3809100A AU3809100A (en) | 2000-10-09 |
| AU771819B2 true AU771819B2 (en) | 2004-04-01 |
Family
ID=7901787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU38091/00A Ceased AU771819B2 (en) | 1999-03-20 | 2000-03-08 | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1162957A1 (en) |
| JP (1) | JP2002539238A (en) |
| KR (1) | KR20010114231A (en) |
| CN (1) | CN1343117A (en) |
| AR (1) | AR023100A1 (en) |
| AU (1) | AU771819B2 (en) |
| BR (1) | BR0010516A (en) |
| CA (1) | CA2366859A1 (en) |
| DE (1) | DE19912623A1 (en) |
| HK (1) | HK1039277A1 (en) |
| TR (1) | TR200102604T2 (en) |
| WO (1) | WO2000056289A1 (en) |
| ZA (1) | ZA200107523B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10053375C1 (en) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber |
| AU2004212675B2 (en) | 2003-02-21 | 2006-06-01 | Bayer Intellectual Property Gmbh | UV stable transdermal therapeutic plaster |
| DE10317692A1 (en) | 2003-04-17 | 2004-11-11 | Lts Lohmann Therapie-Systeme Ag | Medical active substance patches with reduced optical conspicuity on the skin |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| EP1813274B1 (en) * | 2004-10-06 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Medicinal composition, process for producing the same, and method of stabilizing dihydropyridine compound in medicinal composition |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| DE102010050242A1 (en) | 2010-10-30 | 2012-05-03 | Schott Ag | Drug package for delivery of drugs, and for encapsulation and storage of fragrances and chemical indicators, comprises impermeable surface shaped cavity made of thin glass, where cavity is provided for containing active ingredient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0556158A1 (en) * | 1992-02-14 | 1993-08-18 | Ciba-Geigy Ag | Process for preparing ultrasonically sealed transdermal drug delivery systems |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5832821A (en) * | 1981-08-20 | 1983-02-25 | Sumitomo Bakelite Co Ltd | Light screening packaged material containing photodegradable medicine |
| DE3376198D1 (en) * | 1983-11-30 | 1988-05-11 | Siegfried Ag | Therapeutic coronary composition in the form of soft gelatine capsules |
| JPS61293911A (en) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | Sustained release preparation |
| JPH03145421A (en) * | 1989-10-31 | 1991-06-20 | Zeria Pharmaceut Co Ltd | Stable eye drop |
| HUT59592A (en) * | 1990-07-20 | 1992-06-29 | Egyt Gyogyszervegyeszeti Gyar | Process for the preparation of solid medical products |
| JPH07204251A (en) * | 1993-10-15 | 1995-08-08 | Dai Ichi Seiyaku Co Ltd | Quinolon antibacterial preparations |
-
1999
- 1999-03-20 DE DE19912623A patent/DE19912623A1/en not_active Withdrawn
-
2000
- 2000-03-08 KR KR1020017012002A patent/KR20010114231A/en not_active Ceased
- 2000-03-08 AU AU38091/00A patent/AU771819B2/en not_active Ceased
- 2000-03-08 JP JP2000606195A patent/JP2002539238A/en active Pending
- 2000-03-08 EP EP00916905A patent/EP1162957A1/en not_active Ceased
- 2000-03-08 CN CN00804858A patent/CN1343117A/en active Pending
- 2000-03-08 CA CA002366859A patent/CA2366859A1/en not_active Abandoned
- 2000-03-08 TR TR2001/02604T patent/TR200102604T2/en unknown
- 2000-03-08 BR BR0010516-3A patent/BR0010516A/en not_active Application Discontinuation
- 2000-03-08 WO PCT/EP2000/001986 patent/WO2000056289A1/en not_active Ceased
- 2000-03-08 HK HK02100761.5A patent/HK1039277A1/en unknown
- 2000-03-17 AR ARP000101193A patent/AR023100A1/en unknown
-
2001
- 2001-09-12 ZA ZA200107523A patent/ZA200107523B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0556158A1 (en) * | 1992-02-14 | 1993-08-18 | Ciba-Geigy Ag | Process for preparing ultrasonically sealed transdermal drug delivery systems |
Non-Patent Citations (1)
| Title |
|---|
| DERWENT AN 1995/307213 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3809100A (en) | 2000-10-09 |
| CN1343117A (en) | 2002-04-03 |
| ZA200107523B (en) | 2002-11-27 |
| TR200102604T2 (en) | 2002-01-21 |
| JP2002539238A (en) | 2002-11-19 |
| AR023100A1 (en) | 2002-09-04 |
| CA2366859A1 (en) | 2000-09-28 |
| HK1039277A1 (en) | 2002-04-19 |
| BR0010516A (en) | 2003-07-22 |
| EP1162957A1 (en) | 2001-12-19 |
| KR20010114231A (en) | 2001-12-31 |
| WO2000056289A1 (en) | 2000-09-28 |
| DE19912623A1 (en) | 2000-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tønnesen | Formulation and stability testing of photolabile drugs | |
| US9095691B2 (en) | UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix | |
| US4904699A (en) | Nifedipine concentrate stabilized against the influence of light and a process for its preparation | |
| AU771819B2 (en) | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof | |
| Baertschi et al. | Implications of in-use photostability: Proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 2: Topical drug product | |
| ES2204732T3 (en) | TRANSDERMAL THERAPEUTIC SYSTEMS WITH IMPROVED STABILITY AND A PROCEDURE FOR PREPARATION. | |
| US20030102246A1 (en) | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof | |
| EP2259801B1 (en) | Stable pharmaceutical compositions of carvedilol | |
| Ragno et al. | Photostabilization of 1, 4-dihydropyridine antihypertensives by incorporation into β-cyclodextrin and liposomes | |
| RU2336866C2 (en) | Invisible on skin plaster, containing active substance | |
| Teraoka et al. | Quantitative design for photostabilization of nifedipine by using titanium dioxide and/or tartrazine as colourants in model film coating systems | |
| JP2020518553A (en) | Transparent transdermal therapeutic system containing nicotine | |
| MXPA01009137A (en) | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof | |
| Thoma et al. | Photostabilization of solid and semisolid dosage forms | |
| CA2605112C (en) | Solid transdermal therapeutic system comprising uv absorber | |
| KR100702755B1 (en) | Transdermal Therapy System With Improved Stability And Method Of Making The Same | |
| JPS5832821A (en) | Light screening packaged material containing photodegradable medicine | |
| JPH07204251A (en) | Quinolon antibacterial preparations | |
| Asker | Photostability studies of solutions and methods of preventing photodegradation | |
| Garg | Formulation of an oral controlled release dosage form for nifedipine | |
| CN100562310C (en) | UV stabilized transdermal plaster | |
| HK1085394B (en) | Uv stable transdermal therapeutic plaster | |
| HK40003119A (en) | Solid transdermal therapeutic system comprising uv absorber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |